

PARADIGM TO PRESENT AT NWR VIRTUAL HEALTHCARE CONFERENCE

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce that it will present at the NWR Virtual Healthcare Conference. Paradigm’s Managing Director, Mr Paul Rennie will present at 1:00pm AEDT on Wednesday 22 March 2023.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

https://us02web.zoom.us/webinar/register/WN_j9H4e1w6QNSStXWNFqyyoQ

A copy of the presentation will be available on the Paradigm website prior to the conference via:

<https://paradigmbiopharma.com/performance-progress/#announcements>.

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels. Questions can be submitted on the day or sent in advance to:

matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3 clinical trial) and mucopolysaccharidosis (phase 2 clinical trial).

Authorised for release by Paradigm Managing Director, Mr Paul Rennie

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd.
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com